Business
Onconetix Highlights Realbotix's Role in Ericsson's World-First 6G Trial Demonstration
Realbotix Humanoid Robot — Ericsson’s First Enterprise Robotics Client — Fea...
About this update from Onco-innovations Ltd.
[{"type":"text","content":"Onconetix Highlights Realbotix’s Role in Ericsson’s World-First 6G Trial Demonstration\nRealbotix Humanoid Robot — Ericsson’s First Enterprise Robotics Client — Featured as Live Connected Endpoint in Pre-Standard 6G Over-the-Air Trial at Ericsson’s U.S. Headquarters; Onconetix Has Entered into a Definitive Agreement to Acquire Realbotix CINCINNATI, Ohio, March 25, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) wishes to draw its shareholders’ attention to a development reported by Realbotix Corp. (TSX-V: XBOT; Frankfurt: 76M0.F; OTC: XBOTF) (“Realbotix Corp.”), the parent company of Realbotix LLC, the target of Onconetix’s previously announced pending acquisition. Realbotix Corp. announced that one of its humanoid robots, which had been purchased by Ericsson — Realbotix’s first enterprise client — was featured in Ericsson’s recently completed live pre-standard 6G over-the-air (OTA) trial conducted at Ericsson’s U.S. headquarters in Plano, Texas. Onconetix is sharing this development with its shareholders as it relates to the capabilities of Realbotix, the target of the pending acquisition. During the demonstration, the Realbotix humanoid robot served as a live robotics endpoint, transmitting video and interacting in real time over Ericsson’s test network. Ericsson’s demonstration showcased how next-generation wireless networks can power AI robotics and real-time video streaming, highlighting the type of high-speed, low-latency connectivity expected to support future AI-driven technologies. The demonstration also highlighted Realbotix’s AI-agnostic architecture, which enables its humanoid robots to integrate with a variety of AI systems, cloud platforms, and network environments. This flexible approach is designed to allow Realbotix robots to operate across diverse ecosystems without dependence on any single AI provider or software stack. As previously announced on February 12, 2026, Onconetix entered into a definitive share exchange agreement to acquire 100% of the issued and outstanding equity interests of Realbotix LLC, a wholly-owned subsidiary of Realbotix Corp., in an all-stock transaction. The combined company is expected to trade o...